BMEA earnings analysis
What we found in BMEA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Biomea Fusion reported a significant reversal in EPS to $0.27 for Q4 2025 after a series of losses in previous quarters, although revenue remained at $0. Overall, operating expenses were reduced notably to $12.8 million from $29.7 million year-over-year due to decreased R&D and general expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong EPS Recovery
- EPS flipped to $0.27 from a loss of $0.27 in Q3 2025.
- Operating Expenses Cut
- Operating expenses decreased significantly by approximately $17 million, down to $12.8 million from $29.7 million YoY.
- R&D Decrease
- R&D expenses were $9.1 million, compared to $22.9 million in the same quarter last year.
- Cash Position Sustained
- Cash, cash equivalents, and restricted cash stood at $45.1 million as of March 31, 2026.
- Clinical Trials Progress
- Icovamenib continues to show promise with ongoing clinical trials; FDA lifted hold on its IND applications.
- Lifecycle Management Improvement
- Efficiency gains from reduced headcount led to better management of R&D expenses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Revenue Generation
- Continues to report $0 in revenue since inception.
- Significant Accumulated Deficit
- The accumulated deficit amounts to $461.5 million, highlighting ongoing losses.
- Regulatory and Operational Risks
- Possible delays in regulatory submissions and approvals could hinder product development.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.27
What they said about what is next.
Management expects to continue incurring significant operational losses.
The filing reads better than the one before it.
What came before.
- 10-K · March 24, 2026
- Biomea Fusion repositioned in 2025 as a clinical‑stage diabetes and obesity company focused on two internal programs: icovamenib (oral menin inhibitor) and BMF‑650 (oral GLP‑1 RA). The company reports promising Phase II…
- 10-Q · August 5, 2025
- Biomea Fusion reported a materially smaller quarterly loss as operating expenses were cut nearly in half: net loss for Q2 2025 was $(20.74)m (−$0.51/share) versus $(37.28)m (−$1.03/share) in Q2 2024. Cash improved…
- 10-Q · May 5, 2025
- Biomea Fusion reported a narrower Q1 2025 net loss of $29,262 (thousands) vs $39,061 (thousands) in Q1 2024 and improved EPS to $(0.80) from $(1.09). Operating expenses declined (total operating expenses $29,712 vs…
- 10-Q · October 29, 2024
- Biomea Fusion (BMEA) reported a Q3 net loss of $32.8M (EPS $(0.91)), wider than Q3 2023 loss of $28.4M (EPS $(0.80)) but improved versus the prior quarter (Q2 2024 EPS $(1.03) to $(0.91)). Cash declined materially to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BMEA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever